Objectif We advocate the hypothesis that successful chemotherapeutics can induce a type of tumor cell stress and death that is immunogenic, meaning that the patient’s dying cancer cells serve as a vaccine that stimulates a specific antitumor immune response, which in turn can control (and sometimes even eradicate) residual cancer cells. This is a highly original – and necessarily controversial – “breakthrough” concept since it challenges previous belief that anticancer chemotherapies act solely on the tumor cells, without any significant involvement of the host immune system. Cell death is usually non-immunogenic, and only a small minority of chemotherapeutic agents can induce immunogenic cell death, which - in contrast to classical apoptosis - is preceded by two types of pre-mortem stress, autophagy (which is required for cellular ATP release, an obligatory signal of immunogenicity) and endoplasmic reticulum (ER) stress (which is required for calreticulin [CRT] exposure at the cell surface, another obligatory signal of immunogenicity). Here, we will explore the hypothesis that cancer cell death is only immunogenic if the two pathways of pre-mortem stress, autophagy and ER stress, are simultaneously activated. Thus, we aim at “decoding” the anticancer drug-induced cellular pathways that regulate the immunogenicity of cell death. For this, we will trigger cancer cell death preceded by one or the two types of pre-mortem stress in a “synthetic system” (by genetic manipulation involving inducible transgenes in cancer cells and mice) or by means of selected pharmacological compounds in multiple in vitro and in vivo cancer models, as we monitor the immune-dependent therapeutic response. Moreover, we will investigate the functional links between autophagy, ER stress and immunogenic signaling. Finally, we will explore the translational relevance of these findings on human cancers. Champ scientifique medical and health sciencesmedical biotechnologygenetic engineeringmedical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsvaccinesmedical and health sciencesclinical medicineoncologymedical and health sciencesbasic medicineimmunologyimmunotherapy Programme(s) FP7-IDEAS-ERC - Specific programme: "Ideas" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013) Thème(s) ERC-AG-LS4 - ERC Advanced Grant - Physiology, Pathophysiology and Endocrinology Appel à propositions ERC-2012-ADG_20120314 Voir d’autres projets de cet appel Régime de financement ERC-AG - ERC Advanced Grant Institution d’accueil INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE Contribution de l’UE € 2 500 000,00 Adresse RUE DE TOLBIAC 101 75654 Paris France Voir sur la carte Région Ile-de-France Ile-de-France Paris Type d’activité Research Organisations Contact administratif Saliha Cantacuzeme (Mrs.) Chercheur principal Guido Peter Krömer (Prof.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée Bénéficiaires (1) Trier par ordre alphabétique Trier par contribution de l’UE Tout développer Tout réduire INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE France Contribution de l’UE € 2 500 000,00 Adresse RUE DE TOLBIAC 101 75654 Paris Voir sur la carte Région Ile-de-France Ile-de-France Paris Type d’activité Research Organisations Contact administratif Saliha Cantacuzeme (Mrs.) Chercheur principal Guido Peter Krömer (Prof.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée